Therapeutic drug monitoring for dose optimization in Alzheimer's disease and in dementia with Lewy bodies: A randomized single-blinded clinical trial
Michael Hén Forbord Fischer, Ivan Chrilles Zibrandtsen, Peter Johannsen, Volkert Siersma, Jan Borg Rasmussen, Jens Borggaard Larsen, Peter Høgh · 2024
Read Therapeutic drug monitoring for dose optimization in Alzheimer's disease and in dementia with Lewy bodies: A randomized single-blinded clinical trial by Michael Hén Forbord Fischer, Ivan Chrilles Zibrandtsen, Peter Johannsen, Volkert Siersma, Jan Borg Rasmussen, Jens Borggaard Larsen, Peter Høgh (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11863742.txt.
Description
Two standard dementia drugs work better for some patients than others, and blood levels vary a lot between people on the same dose. Michael Fischer and co-authors ran a trial to test whether dose tuning by blood test beats tuning by feel in this 2024 paper. Patients had Alzheimer disease or Lewy body dementia and were starting one of the two drugs.
Half the patients, picked by chance, had doses set using blood level checks, while the other half had doses set by clinical judgment alone. Neither patients nor outcome raters knew the group split in this single-blind design. Thinking scores, behavior scores, and side effects were tracked. If blood-based tuning wins, memory clinics could adopt a simple test to get more benefit from old, cheap drugs.
Catalog record
| CREATOR | Michael Hén Forbord Fischer, Ivan Chrilles Zibrandtsen, Peter Johannsen, Volkert Siersma, Jan Borg Rasmussen, Jens Borggaard Larsen, Peter Høgh |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 42 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |